Spirolactam Derivatives Allosteric Modulation mGlu5 Receptor
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for central nervous system disorders using mGlu5 receptor modulators face limitations such as low brain penetration, insufficient selectivity, potential receptor desensitization, and prolonged receptor blockade, which can be addressed through allosteric modulation for a more controlled and selective action.
Innovation Solution
Development of spirolactam derivatives that act as allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5), offering a compound of formula (I) and its pharmaceutical compositions for treating central nervous system diseases by administering a therapeutically effective amount to a mammal in need.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If synthetic agonists are used to stimulate mGlu5 receptors, then receptor activation is achieved, but continuous stimulation occurs leading to receptor desensitization
Solution Approach 1:
The patent employs allosteric modulators that provide periodic or controlled receptor modulation rather than continuous stimulation. These modulators bind to allosteric sites and induce conformational changes that enhance or suppress orthosteric ligand binding in a controlled manner, allowing transient or fine-tuned receptor activation that prevents desensitization while maintaining therapeutic effect.
Solution Approach 2:
The patent introduces allosteric modulators as intermediary substances that do not directly activate the receptor but instead modify the receptor's response to orthosteric ligands. These modulators bind to allosteric sites and alter the receptor's conformation, thereby controlling the duration and intensity of receptor activation without causing continuous stimulation.
2Reliability
If synthetic antagonists are used to block mGlu5 receptors, then receptor blockade is achieved, but prolonged blockade occurs which is not compatible with pathology kinetics
Solution Approach 1:
The patent employs allosteric modulators that provide periodic or controlled receptor modulation rather than continuous stimulation. These modulators bind to allosteric sites and induce conformational changes that enhance or suppress orthosteric ligand binding in a controlled manner, allowing transient or fine-tuned receptor activation that prevents desensitization while maintaining therapeutic effect.
Solution Approach 2:
The patent utilizes allosteric modulators that change the functional parameters of the receptor by binding to allosteric sites. These modulators alter the receptor's affinity for orthosteric ligands, the duration of receptor activation, and the magnitude of receptor response, thereby achieving controlled blockade that matches the kinetics of central nervous system disorders.
3Reliability
If glutamate analogs target the orthosteric binding site, then receptor activation is achieved, but low brain penetration and insufficient selectivity occur
Solution Approach 1:
The patent introduces allosteric modulators as intermediary substances that do not directly activate the receptor but instead modify the receptor's response to orthosteric ligands. These modulators bind to allosteric sites and alter the receptor's conformation, thereby controlling the duration and intensity of receptor activation without causing continuous stimulation.
Solution Approach 2:
The patent targets specific allosteric sites on the mGlu5 receptor that are distinct from the orthosteric binding site. By binding to these localized allosteric sites, the modulators achieve high selectivity for the mGlu5 receptor subtype while maintaining brain penetration, as the allosteric sites are accessible to centrally acting compounds.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides spirolactam derivatives of formula (I): wherein R1 - R7 are as defined herein; or a pharmaceutically acceptable salt thereof; and pharmaceutical compositions and uses of the same.